SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Madrigal Pharmaceuticals
MDGL 418.90-2.0%Oct 31 9:30 AM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: keokalani'nui9/22/2019 4:16:22 PM
   of 138
 
Has MDGL said anything about their or others' progress in developing non-invasive fibrosis staging "comparable or superior" to biopsy? (Quote is from fda draft nash guidance.) I assume it would take the form of improved MRI or US. I poke around the internet and all it see is still 'there is a need for improved methods and validated studies.....'

I'm not sure any non-invasive staging today is actually "comparable or superior" to biopsy in nash.

If one is never adopted for commercial practice, maybe this makes the dislipidemia trial actually the key P3 for mdgl.
This is the sort of question that might get answered in the C-suite but not in an event or presentation that I might have access to.



    • Report TOU ViolationShare This Post
     Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

    HomeMailHotSubjectMarksPeopleMarksKeepersSettings
    Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
    © 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News